CSIR-National Chemical Laboratory, Pune 411008, India.
CSIR-National Chemical Laboratory, Pune 411008, India; Academy of Scientific and Innovative Research, Ghaziabad 201 002, India.
J Proteomics. 2021 Feb 10;232:104053. doi: 10.1016/j.jprot.2020.104053. Epub 2020 Nov 22.
Therapeutic monoclonal antibodies (mAbs) are structurally large and complex molecules. To be safe and efficacious, a biosimilar mAb must show high similarity to its reference product in Critical Quality Attributes (CQA). mAbs are highly sensitive to protein expression, production, manufacturing, supply chain, and storage conditions. All these factors make biosimilar mAbs intrinsically susceptible for variability during production. Accordingly, several lots of references and tests are required to establish the biosimilarity of a test mAb. The primary structure is a CQA of a mAb affecting its safety and efficacy. Here, we apply peptide mapping as an analytical method to decipher the primary structure and associated modifications for a quick quality assessment of TrastuzumAb and RituximAb innovator and biosimilar. A multiple-parallel-protease digestion strategy followed by high-resolution mass spectrometric analysis consistently achieved 100% sequence coverage along with reliable detection of post-translational modifications. Additionally, the use of supporting methods such as intact mass analysis and circular dichroism helped us to decipher the primary and higher order structures of these mAbs. We identify discernible variations in the profile of the innovator and biosimilar mAbs and validate the method for quick yet deep comparability analysis of the primary structure of biosimilar mAbs sold in the market. SIGNIFICANCE: Peptide mapping using bottom-up approach is one of the most common methods for the characterization of therapeutic monoclonal antibodies. Herein, we describe a multi-parallel-protease digestion strategy using a combination of five different proteases followed by high-resolution mass spectrometric analysis with TrastuzumAb and RituximAb as an example. This resulted in a comprehensive identification of peptides with increased reliability and identification of different PTMs. Additional supporting orthogonal methods like intact mass and higher-order structure analysis helped evaluate broader conformational properties.
治疗性单克隆抗体(mAbs)是结构庞大且复杂的分子。为了安全有效,生物类似药 mAb 必须在关键质量属性(CQA)方面与参比产品表现出高度相似性。mAbs 对蛋白质表达、生产、制造、供应链和储存条件高度敏感。所有这些因素使得生物类似药 mAb 在生产过程中本质上容易发生变异。因此,需要进行多个批次的参比和测试来确定测试 mAb 的生物相似性。一级结构是影响 mAb 安全性和疗效的 CQA。在这里,我们应用肽图作为一种分析方法来解析一级结构和相关修饰,以便快速评估曲妥珠单抗和利妥昔单抗原研药和生物类似药的质量。采用多种平行蛋白酶消化策略,结合高分辨率质谱分析,可实现 100%的序列覆盖率,并可靠地检测到翻译后修饰。此外,使用完整质量分析和圆二色性等支持方法有助于我们解析这些 mAbs 的一级和高级结构。我们发现原研药和生物类似药 mAb 的图谱存在明显差异,并验证了该方法可快速且深入地比较市售生物类似药 mAb 的一级结构。意义:采用自上而下的方法进行肽图分析是治疗性单克隆抗体表征的最常用方法之一。在此,我们以曲妥珠单抗和利妥昔单抗为例,描述了一种采用五种不同蛋白酶组合的多平行蛋白酶消化策略,结合高分辨率质谱分析。这可提高肽鉴定的可靠性并鉴定不同的 PTMs。额外的支持性正交方法,如完整质量和高级结构分析,有助于评估更广泛的构象特性。